FDA CLIA Waiver Evaluation Will Focus On User Comparability
This article was originally published in The Gray Sheet
Executive Summary
FDA is planning to focus on operator rather than product characteristics when evaluating CLIA waiver applications inherited from the Centers for Disease Control and Prevention, the agency indicates.
You may also be interested in...
CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies
Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.
CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies
Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.
CLIAC Seeks Role In FDA's Revision Of Lab Test Waiver Policy
The Clinical Laboratory Improvement Advisory Committee (CLIAC) requests that FDA postpone guidance or rulemaking on CLIA waiver applications until it makes recommendations on the issue at a February or March 2001 meeting.